Tin tức & Cập nhật

The prescribing patterns for acne among local primary care physicians appear to deviate from clinical practice guidelines used to achieve optimal outcomes for young people, as shown in a Singapore study.

Treatment with apremilast demonstrates consistent efficacy in genital psoriasis and overall psoriasis symptoms at 16 weeks irrespective of body surface area (BSA) at baseline, suggest the results of the phase III DISCREET trial presented at the recent AAD 2023.

Treatment with lebrikizumab with or without topical corticosteroids (TCS) results in clinical improvement among adolescents with moderate-to-severe atopic dermatitis (AD), according to a study presented at the recent AAD 2023.

Data presented at AAD 2023 underpin the potential of upadacitinib, a selective Janus kinase inhibitor, to provide long-term improvements in patient-reported outcomes (PROs; skin symptoms, sleep, and quality of life [QoL]) in individuals with moderate-to-severe atopic dermatitis (AD).

Patients with melanoma of unknown primary (MUP) benefit from novel therapies similarly as those with stage-matched melanoma of known cutaneous primary (cMKP) despite having less favourable baseline prognostic factors, reveals a study.

The performance of a prognostic model with sentinel lymph node (SLN) biopsy status in assessing patient risk for 5-year melanoma-specific death is superior to that of a model with primary tumour staging factors alone for threshold mortality rates ≥30 percent, a study has shown.